Results 91 to 100 of about 45,532 (172)

Cytomegalovirus Infection Mimics Manifestations of Underlying Diseases in Patients With Autoimmune Disorders: A Case Report and Literature Review

Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.
Autoimmune disorder patients are vulnerable to cytomegalovirus (CMV) infections, which can present with symptoms that mimic flare‐ups of the underlying disease. We present two cases: a 44‐year‐old woman with systemic lupus erythematosus and a 55‐year‐old man with sarcoidosis, both of whom developed unusual manifestations linked to CMV infection ...
Elaheh Karimi, Zahra Moradi, Somayeh Soroureddin, Ozra Nouri, Zahra Tamartash, Hoda Kavosi   +5 more
wiley   +1 more source

CORRELATION BETWEEN SGOT AND SGPT LEVELS WITH POSITIVE HBsAg LEVELS

Journal of Vocational Health Studies
Background: Serum Glutamic Oxaloacetate Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT) are transaminase enzymes used to determine liver damage. The increase in both enzymes can indicate the level of liver cell damage.
Nisa'ur Rosyidah, Erlinda Widyastuti, Annisa Auliya Rahman, Nur Septia Handayani, Belgis   +4 more
doaj   +1 more source

Retrospective Analysis of Blood Donor Deferral Reasons and Optimization Suggestions for Deferral Policies

iLABMED, Volume 4, Issue 1, Page 37-46, March 2026.
This retrospective study analyzes the deferral reasons for 148,282 blood donors during 2019–2023 (overall deferral rate: 12.37%), identifying primary deferral reasons (e.g., elevated ALT for temporary deferral at 51.33%, HBsAg positivity for permanent deferral at 4.12%).
Limei Feng, Li Liu, Rui Wang, Ting Zhang, Wei Guo, Yang Yu   +5 more
wiley   +1 more source

Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges.
Sheng‐Jie Shiue, Tung‐Han Ho, Hsin‐Yi Lin, Sheng‐Wei Cheng, Li‐Wei Wu, Tze‐Sian Chan, Chun‐Nan Chen, Chao‐Ling Cheng, Yan Kang Lee, Hsien‐Yao Yang, Han‐Shiang Shiue, Kuo‐Feng Leng, Ming‐Shun Wu   +12 more
wiley   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, Volume 46, Issue 2, Page 475-512, March 2026.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source

Advances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Chronic viral hepatitis, predominantly caused by HBV and HCV infections, remains a major global health burden and a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver‐related mortality. Achieving the World Health Organisation (WHO) target of diagnosing 90% of HBV and HCV infections by 2030 necessitates a fundamental ...
Hsin‐Ying Ho, Chia‐Yen Dai, I‐Jung Feng, Yen‐Hsu Chen, Ming‐Lung Yu, Che‐Hsin Lin, Ling‐Shan Yu   +6 more
wiley   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 5, Page 592-602, March 2026.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Population‐Based Molecular Surveillance of Hepatitis B Virus Genotypes in the Goto Islands, Japan: A Three Decade Study (1977–2008) of 916 Carriers

Hepatology Research, Volume 56, Issue 3, Page 292-301, March 2026.
ABSTRACT Aims Understanding the molecular characteristics and genotype distribution of hepatitis B virus (HBV) is essential to elucidate intra and inter community transmission routes, identify cluster cases, and assess clinical implications based on genotype‐specific virulence.
Ko Ko, Golda Akuffo Ataa, Kazumi Yamasaki, Kazuhiro Hirase, Takahiro Yasaka, Satoshi Shirahama, Tomoyuki Akita, Aya Sugiyama, Shingo Fukuma, Kazuaki Takahashi, Junko Tanaka   +10 more
wiley   +1 more source

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction–Associated Steatotic Liver Disease

Journal of Gastroenterology and Hepatology, Volume 41, Issue 3, Page 1041-1051, March 2026.
ABSTRACT Background/Aims Benefits of the Mediterranean diet (MD) in reducing hepatic steatosis among individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) have been well established. This study aims to evaluate the relationship between MD adherence and liver fibrosis among the MASLD population.
Meng‐Lun Hsieh, Tung‐Hung Su, Ying‐Cheng Lin, Yen‐Yang Chen, Chun‐Fang Tung, Ling‐Sung Huang, Cheng‐Hao Wu, Yen‐Chun Peng, Vivian Chia‐Rong Hsieh   +8 more
wiley   +1 more source

All‐Cause Mortality in Persons With HIV‐HBV Co‐Infection Treated for HBV in Rwanda: A Population‐Based Cohort Study

Journal of Viral Hepatitis, Volume 33, Issue 3, March 2026.
ABSTRACT Chronic hepatitis B virus (HBV) infection increases the risk of cirrhosis, hepatocellular carcinoma and non‐liver complications. HIV co‐infection accelerates disease progression and increases mortality risk compared to HBV mono‐infection, but its impact among treated individuals is not well documented in Sub‐Saharan Africa.
Jean Damascene Makuza, Michael Law, Joseph Puyat, Alnoor Ramji, Dahn Jeong, Richard L. Morrow, Prince Asumadu Adu, Marie Paul Nisingizwe, Alpamys Issanov, Georgine Cua, Héctor Alexander Velásquez García, Charles Berabose, Albert Tuyishime, Naveed Zafar Janjua   +13 more
wiley   +1 more source